All Posts Tagged With: "clinical trial retention"
Addressing Clinical Trial Recruitment and Retention Issues Imposed by HIPAA Step by Step (second of a series)
Clinical Trial Recruitment
Recent reports have indicated that the Health Insurance Portability and Accountability Act (HIPAA) that went into effect in 2003 has adversely affected clinical trial conduct by imposing significant time and cost burdens, and by impeding clinical trial recruitment and retention,1 which in turn has deterred finding patients lost-to-follow-up (LTFU). This post will serve [...]
Find Patient | Find Patient Fast - Improve Clinical Trial Retention
Patient Find
Patient Recruiters, Principal Investigators and Study Coordinators can greatly improve clinical trial retention and reduce patients lost to follow-up by simply obtaining more contact information when the patient is first recruited into a study. Detailed contact information will allow a search company, such as OmniTrace, many more avenues to find a patient in the event the patient becomes [...]
Efficiency of Clinical Trials Require Effective Recruitment, Retention and Return
Efficiency of Clinical Trials
Conducting clinical trials is becoming increasingly arduous for drug manufactures due to several factors including: (a) heightened food and drug (FDA) regulatory scrutiny based on recent safety concerns; (b) inefficiencies and/or unclear guidance imposed by Health Insurance Portability and Accountability Act (HIPAA) guidelines in the research, design, enrollment and follow-up processes; (c) [...]
Clinical Trial Recruitment | Retention Issues for Manufacturers of Diabetes Agents
Clinical Trial Recruitment | Retention
Anxiety lurks among manufacturers of type 2 diabetes drugs, especially those manufacturers who have drugs in late clinical development.
Recent FDA advisory committee recommendations have created an ongoing debate over whether Investigational diabetes agents should be subject to long-term cardiovascular safety. 1 A firm consensus has not been reached, however, several manufacturers [...]
FDA Patient Safety News- Recalls and Safety Alerts: Serious Fungal Infections with Humira, Cimzia, Enbrel and Remicade November 1, 2008
- Recalls and Safety Alerts: Serious Injection Site Reactions with Vivitrol November 1, 2008
- Recalls and Safety Alerts: Updated Warning on Byetta November 1, 2008
- Recalls and Safety Alerts: Importance of Influenza Vaccination for Health Care Personnel November 1, 2008
- Recalls and Safety Alerts: Increased Risk of Death in Elderly Patients Taking Conventional Antipsychotics for Dementia November 1, 2008
